UPDATE: SentinelOne Inc (S) PT Lowered to $48 at BTIG

UPDATE: SentinelOne Inc (S) PT Lowered to $65 at Cowen

(Updated - March 16, 2022 6:16 AM EDT)

Cowen analyst Shaul Eyal lowered the price target on SentinelOne Inc (NYSE: S) to $65.00 (from $77.00) while maintaining a Outperform rating.

The analyst comments "S reported strong F4Q22 results, with revenue up 120% y/y and... More

SentinelOne Inc (S) PT Lowered to $37 at Barclays

Barclays analyst Kannan Venkateshwar lowered the price target on SentinelOne Inc (NYSE: S) to $37.00 (from $39.00) while maintaining a Overweight rating.... More

UPDATE: SentinelOne Inc (S) PT Lowered to $54 at BofA Securities

(Updated - March 16, 2022 6:16 AM EDT)

BofA Securities analyst Tai Liani lowered the price target on SentinelOne Inc (NYSE: S) to $54.00 (from $67.00) while maintaining a Buy rating.

The analyst comments "While SentinelOne is still in the early innings, we see strong... More

UPDATE: SentinelOne Inc (S) PT Lowered to $38 at Wolfe Research

(Updated - March 16, 2022 6:18 AM EDT)

Wolfe Research analyst Joshua Tilton lowered the price target on SentinelOne Inc (NYSE: S) to $38.00 (from $52.00) while maintaining a Outperform rating.

The analyst comments "SentinelOne reported 4Q results that were ahead of consensus across key... More

SentinelOne Inc (S) PT Lowered to $56 at UBS

UBS analyst Roger Boyd lowered the price target on SentinelOne Inc (NYSE: S) to $56.00 (from $75.00) while maintaining a Neutral rating.... More

After-Hours Stock Movers 03/15: (CBIO) (IOVA) (MKFG) Higher; (SMAR) (BRDS) (S) Lower (more...)

After-Hours Stock Movers:

Catalyst Biosciences, Inc. (NASDAQ: CBIO) 18% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 12.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an... More

SentinelOne (S) Shares Drop 6% Despite Q4 Beat

SentinelOne, Inc. (NYSE: S) shares were trading around 6% lower after-hours despite a Q4 beat and better than expected guidance.

EPS for the fourth quarter came in at ($0.17), slightly better than the consensus estimate of ($0.18). Revenue grew 120% year-over-year to $65.6 million, compared to the consensus estimate of... More

SentinelOne, Inc. (S) Tops Q4 EPS by 1c; Guides Higher

SentinelOne, Inc. (NYSE: S) reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million.

GUIDANCE:

SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of... More

SentinelOne, Inc. (S) Acquires Attivo Networks for $616.5M Cash and Stock

SentinelOne (NYSE: S), an autonomous cybersecurity platform company, today announced it has entered into a definitive agreement to acquire... More